法布瑞氏病[1]Fabry diseaseFabry's diseaseAnderson-Fabry disease)又稱法布里病,是一種X連鎖隱性遺傳的溶酶體貯積病,由於GLA基因突變致使細胞溶酶體內鞘糖脂代謝異常且累積[2][3]。它的命名來自於它的發現者之一,喬納斯·法布瑞[4](Johannes Fabry)。

法布瑞氏病
阿加糖酶β - 這種蛋白質在法布瑞氏病患者身上產生異常
症狀疼痛限制型心肌病[*]高血壓腎功能衰竭angiokeratoma[*]無汗症[*]cornea verticillata[*]神經病噁心疲倦vertigochronic neuropathic pain[*]
類型sphingolipidosis[*]developmental anomaly of metabolic origin[*]genetic skin vascular disorder[*]rare genetic epilepsy[*]syndromic dyslipidemia[*]vascular skin disease[*]肥厚性梗阻型心肌病[*]sphingolipidosis with epilepsy[*]syndromic lymphedema[*]nephropathy secondary to a storage or other metabolic disease[*]cataract associated with a metabolic disease[*]metabolic disease with corneal opacity[*]lysosomal disease with restrictive cardiomyopathy[*]lysosomal disease with hypertrophic cardiomyopathy[*]rare hereditary metabolic disease with peripheral neuropathy[*]syndrome associated with hypertrophic cardiomyopathy[*]疾病
治療酵素替代療法[*]
分類和外部資源
醫學專科內分泌學、​腎臟科、​皮膚病學、​心臟科
ICD-115C56.01
OMIM301500
DiseasesDB4638
eMedicine951451
Orphanet324
[編輯此條目的維基數據]

病因

編輯

此病體內負責製造α-galactosidase(a-GAL)酵素的基因缺陷,造成體內醣神經胺醇脂質(glycosphingolipid)無法代謝,不斷堆積在細胞質溶體中,而引發多處器官病變,且引起機體內一系列臟器的缺血性損害,嚴重時可能造成死亡[5][6][7]

症狀

編輯

此病的臨床症狀多變。患者在兒童或青年期,手腳末端會產生間歇性的疼痛或感覺異常,有些患者形容如火燒般劇痛,在高溫、季節變化、及運動後容易產生[8]。經常被誤診為風濕病關節炎關節痛生長痛或是心因性疼痛

治療方式

編輯

目前採取酵素替代療法,讓患者兩週一次,注射α-galactosidase(a-GAL)酵素藥劑,可以有效緩解病情[9]

參考文獻

編輯
  1. ^ Fabry氏病. 樂詞網. 國家教育研究院.  (繁體中文)
  2. ^ Schiffmann R. Fabry disease. Neurocutaneous Syndromes. Handbook of Clinical Neurology 132. 2015: 231–248. ISBN 9780444627025. PMID 26564084. doi:10.1016/B978-0-444-62702-5.00017-2. 
  3. ^ James, William D.; Elston, Dirk; Berger, Timothy. Andrews' Diseases of the Skin E-Book: Clinical Dermatology. Elsevier Health Sciences. 2015-04-12. ISBN 978-0-323-31969-0 (英語). 
  4. ^ Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae) [A contribution to the knowledge of the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Archiv für Dermatologie und Syphilis. December 1898, 43 (1): 187–200 [2024-09-04]. S2CID 33956139. doi:10.1007/bf01986897 (不活躍 13 August 2024). (原始內容存檔於2022-01-25) (德語). 
  5. ^ Germain DP. Fabry disease. Orphanet Journal of Rare Diseases. November 2010, 5 (1): 30. PMC 3009617 . PMID 21092187. doi:10.1186/1750-1172-5-30 . 
  6. ^ Fabry disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. rarediseases.info.nih.gov. [17 April 2018]. (原始內容存檔於2018-04-18) (英語). 
  7. ^ Perrot A, Osterziel KJ, Beck M, Dietz R, Kampmann C. Fabry disease: focus on cardiac manifestations and molecular mechanisms. Herz. November 2002, 27 (7): 699–702. PMID 12439642. S2CID 25962218. doi:10.1007/s00059-002-2429-9. 
  8. ^ Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey. The Clinical Journal of Pain. July 2007, 23 (6): 535–542. PMID 17575495. S2CID 36215895. doi:10.1097/AJP.0b013e318074c986. 
  9. ^ Keating GM. Agalsidase alfa: a review of its use in the management of Fabry disease. BioDrugs. October 2012, 26 (5): 335–354. PMID 22946754. doi:10.2165/11209690-000000000-00000. 

外部連結

編輯
Support groups